| Symbol | LNTH |
|---|---|
| Name | LANTHEUS HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Address | 331 TREBLE COVE ROAD, NORTH BILLERICA, Massachusetts, 01862, United States |
| Telephone | +1 978 671-8001 |
| Fax | — |
| — | |
| Website | https://www.lantheus.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001521036 |
| Description | Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. Its portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States. Additional info from NASDAQ: |
2026-05-18 20:37
Director McHugh Julie 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000211
Read more
2026-05-18 20:37
Director Morrow Phuong Khanh 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000210
Read more
2026-05-18 20:36
Director Maeusli Heinz Christoph 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000209
Read more
2026-05-18 20:36
Director LENO SAM R 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000208
Read more
2026-05-18 20:35
Director Pruden Gary J 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000207
Read more
2026-05-18 20:35
Director Baylor-Henry Minnie 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000206
Read more
2026-05-18 20:35
Director Ber Gerard 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000205
Read more
2026-05-18 20:34
Director EASTLAND JULIA MARIE 🟢 acquired 4.1K shares of Lantheus Holdings, Inc. (LNTH) Transaction Date: May 14, 2026 | Filing ID: 000203
Read more
2026-05-15 13:39
New Form SCHEDULE 13G/A - Lantheus Holdings, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001274173-26-000149 <b>Size:</b> 12 KB
Read more
2026-05-07 11:36
(30% Negative) LANTHEUS HOLDINGS, INC. (LNTH) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06033001 | Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostat… | — | Castration-Resistant Prostatic Cancer | Temporarily_Not_Available | — | — | ClinicalTrials.gov |
| NCT07501650 | Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck C… | Phase1 | Head and Neck Cancer | Recruiting | 2026-03-18 | 2028-03-01 | ClinicalTrials.gov |
| NCT07357519 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | Phase1 | Relapsed / Refractory Osteosarcoma | Recruiting | 2026-02-01 | 2032-05-01 | ClinicalTrials.gov |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metas… | Phase2 | Clear Cell Renal Cell Carcinoma | Withdrawn | 2025-11-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | Phase1 | Metastatic Renal Cell Carcinoma | Withdrawn | 2025-10-01 | 2032-01-01 | ClinicalTrials.gov |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Phase1 | Metastatic Sarcoma | Recruiting | 2025-08-01 | 2026-04-01 | ClinicalTrials.gov |
| NCT07335315 | Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identificatio… | — | Pituitary Adenoma | Recruiting | 2024-06-19 | 2027-01-01 | ClinicalTrials.gov |
| NCT05160480 | A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG | — | Prostate Cancer | Enrolling_By_Invitation | 2024-06-07 | 2026-09-01 | ClinicalTrials.gov |
| NCT06074510 | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prost… | Phase4 | Prostate Cancer | Active_Not_Recruiting | 2024-02-08 | 2026-09-01 | ClinicalTrials.gov |
| NCT05820724 | PSMA PET Scan and mpMRI for Prostate Cancer Detection | Phase2 | Prostate Cancer Diagnosis | Not_Yet_Recruiting | 2023-05-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT05712473 | An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18)… | — | Prostate Cancer | Not_Yet_Recruiting | 2023-02-01 | 2029-06-01 | ClinicalTrials.gov |
| NCT05394259 | A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting M… | Phase1 | Pancreatic Cancer | Recruiting | 2022-10-28 | 2027-02-02 | ClinicalTrials.gov |
| NCT05416385 | Carotid Intraplaque Neovascularization Combined With Stress Echo | — | Atherosclerosis | Recruiting | 2021-08-16 | 2026-08-16 | ClinicalTrials.gov |
| NCT04557501 | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced P… | Phase3 | Prostate Cancer | Active_Not_Recruiting | 2021-01-06 | 2029-01-01 | ClinicalTrials.gov |
| NCT05247541 | Diagnosing Compartment Syndrome With SHAPE vs Elastography | Phase2 | Chronic Exertional Compartment Syndrome | Completed | 2020-07-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT04286100 | Contrast Specific Echocardiogram Versus Left Ventricular Opacification (LVO) Im… | — | Contrast Echocardiography Imaging | Active_Not_Recruiting | 2020-04-29 | 2026-03-01 | ClinicalTrials.gov |
| NCT03907657 | Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients … | Phase2 | Von-Hippel Lindau | Completed | 2019-09-23 | 2023-03-13 | ClinicalTrials.gov |
| NCT03719612 | DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Phase3 | Cardiac Disease | Completed | 2018-12-28 | 2020-01-09 | ClinicalTrials.gov |
| NCT03571672 | DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Phase3 | Cardiac Disease | Completed | 2018-10-24 | 2019-08-30 | ClinicalTrials.gov |
| NCT03493516 | Prediction of ARrhythmic Events With Positron Emission Tomography II | — | Sudden Cardiac Arrest | Active_Not_Recruiting | 2018-04-08 | 2026-12-31 | ClinicalTrials.gov |
| NCT03173716 | Real-Time Myocardial Perfusion Echocardiography in the ICU | Phase4 | Myocardial Perfusion Imaging | Completed | 2017-09-28 | 2019-12-31 | ClinicalTrials.gov |
| NCT03196076 | Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients Wi… | Phase2 | Chronic Kidney Diseases | Completed | 2017-08-28 | 2021-03-19 | ClinicalTrials.gov |
| NCT03297112 | Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization … | Early_Phase1 | Adnexal Mass | Completed | 2017-08-01 | 2018-09-04 | ClinicalTrials.gov |
| NCT03243942 | Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement | Phase2 | Cardiac Catheterization | Completed | 2017-06-01 | 2019-06-26 | ClinicalTrials.gov |
| NCT03466255 | Early Detection of Cardiovascular Disease | — | Atheroma | Completed | 2016-12-06 | 2022-01-11 | ClinicalTrials.gov |
| NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization | Phase3 | Hepatocellular Carcinoma | Completed | 2016-04-01 | 2023-02-01 | ClinicalTrials.gov |
| NCT03674255 | Echocardiography: Value and Accuracy at REst and STress | — | Coronary Artery Disease | Enrolling_By_Invitation | 2015-03-01 | 2033-09-01 | ClinicalTrials.gov |
| NCT04093973 | Bicycle Exercise Echocardiography to Assess Physiological Significance of Mitra… | — | Mitral Annulus Calcification | Completed | 2014-11-07 | 2022-06-30 | ClinicalTrials.gov |
| NCT02086695 | Early Detection of Broken Hearts in Cancer Patients | — | Cardiotoxicity | Completed | 2013-06-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01085162 | A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Pa… | — | Coronary Artery Disease (CAD) | Withdrawn | 2013-03-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01681524 | Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI | Phase3 | Coronary Artery Disease | Withdrawn | 2012-11-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01490892 | Quantitative Subharmonic Breast Imaging | Phase4 | Breast Cancer | Completed | 2011-11-01 | 2019-04-05 | ClinicalTrials.gov |
| NCT01431300 | Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins … | Na | Healthy | Completed | 2011-08-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01165892 | Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosves… | — | Pulmonary Embolism | Completed | 2011-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01384591 | Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative … | Phase1 | Aging | Completed | 2011-07-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01347710 | A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injectio… | Phase3 | Coronary Artery Disease | Completed | 2011-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01085175 | Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at L… | Phase2 | Heart Failure | Withdrawn | 2010-05-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01021865 | Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Typ… | — | Coronary Artery Disease | Completed | 2010-02-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01062178 | Efficacy of Ultrasound Contrast Agent to Assess Renal Masses | Phase2 | Renal Cell Carcinoma | Completed | 2009-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01135316 | Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease … | — | Nephrogenic Systemic Fibrosis | Completed | 2009-10-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01151566 | Can Ultrasound Replace Computed Tomography (CT) Scan in Those Unable to Have Co… | — | Nephrotoxicity of CT Contrast Agents | Completed | 2009-09-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00891241 | A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-… | Phase1 | Heart Failure | Completed | 2009-08-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00918866 | A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary… | Phase4 | Pulmonary Heart Disease | Completed | 2009-07-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00930631 | Study of [3H] BMS747158 in Healthy Male Subjects | Phase1 | Coronary Artery Disease | Completed | 2009-06-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT01436773 | Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Even… | — | Coronary Artery Disease | Completed | 2009-05-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00849108 | Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS7… | Phase2 | Ischemia | Completed | 2009-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01299649 | Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) P… | — | Cardiovascular Disease | Completed | 2008-06-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00707538 | A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following … | Phase1 | Healthy Volunteers | Completed | 2008-06-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00625365 | A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of … | Phase4 | Cardiovascular Disease | Completed | 2008-02-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT01005212 | Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascul… | — | Endoleaks | Completed | 2008-01-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00707499 | A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158 | Phase1 | Healthy | Completed | 2007-09-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00539045 | Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Pos… | — | Thrombus | Completed | 2007-03-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00401687 | DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Us… | Phase4 | Ventricular Ejection Fraction | Completed | 2006-07-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00162032 | A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients Wit… | Phase3 | Kawasaki Disease | Completed | 2005-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00162331 | CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI | Phase4 | Myocardial Infarction | Completed | 2005-01-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00162045 | A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARD… | Phase1 | Kawasaki Disease | Completed | 2005-01-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00162370 | A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronar… | Phase4 | Coronary Artery Disease | Completed | 2004-04-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00162357 | Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Bl… | Phase4 | Diabetes Mellitus, Type 2 | Completed | 2004-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00162058 | A Phase II Study of DMP 115 to Assess Focal Liver Lesions | Phase2 | Liver Disease | Completed | 2004-03-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00162344 | A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary … | Phase4 | Diabetes | Completed | 2003-12-01 | 2005-12-01 | ClinicalTrials.gov |
Total clinical trials: 60
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Technetium Tc99m Sestamibi | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00162357 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE4 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00162357 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT00162344 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE4 | Diabetes | COMPLETED | NCT00162344 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE4 | Myocardial Infarction | COMPLETED | NCT00162331 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE4 | Myocardial Infarction | COMPLETED | NCT00162331 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE4 | Myocardial Infarction | COMPLETED | NCT00162331 |
| Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension | Other | Phase PHASE4 | Ventricular Ejection Fraction | COMPLETED | NCT00401687 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE1 | Kawasaki Disease | COMPLETED | NCT00162045 |
| Technetium Tc99m Sestamibi | Other | Phase PHASE1 | Kawasaki Disease | COMPLETED | NCT00162045 |
| Peflutren Lipid Microsphere Injectable Suspension | Other | Phase PHASE2 | Liver Disease | COMPLETED | NCT00162058 |
| Peflutren Lipid Microsphere Injectable Suspension | Other | Phase PHASE2 | Liver Disease | COMPLETED | NCT00162058 |
| BMS747158 | Other | Preclinical | Coronary Artery Disease (CAD) | WITHDRAWN | NCT01085162 |
| BMS747158 | Other | Preclinical | Coronary Artery Disease (CAD) | WITHDRAWN | NCT01085162 |
| Flurpiridaz F18 | Other | Phase PHASE3 | Coronary Artery Disease | WITHDRAWN | NCT01681524 |
| Flurpiridaz F18 | Other | Phase PHASE3 | Coronary Artery Disease | WITHDRAWN | NCT01681524 |
| gadofosveset | Other | Approved | Healthy | COMPLETED | NCT01431300 |
| Ablavar | Other | Preclinical | Nephrogenic Systemic Fibrosis | COMPLETED | NCT01135316 |
| Ablavar | Other | Preclinical | Nephrogenic Systemic Fibrosis | COMPLETED | NCT01135316 |
| Ablavar | Other | Preclinical | Nephrogenic Systemic Fibrosis | COMPLETED | NCT01135316 |
| Definity | Other | Phase PHASE4 | Pulmonary Heart Disease | COMPLETED | NCT00918866 |
| Definity | Other | Phase PHASE4 | Pulmonary Heart Disease | COMPLETED | NCT00918866 |
| LMI 1195 | Other | Phase PHASE2 | Heart Failure | WITHDRAWN | NCT01085175 |
| LMI 1195 | Other | Phase PHASE2 | Heart Failure | WITHDRAWN | NCT01085175 |
| BMS747158 | Other | Phase PHASE2 | Ischemia | COMPLETED | NCT00849108 |
| BMS747158 | Other | Phase PHASE2 | Ischemia | COMPLETED | NCT00849108 |
| Definity | Other | Phase PHASE2 | Renal Cell Carcinoma | COMPLETED | NCT01062178 |
| Definity | Other | Phase PHASE2 | Renal Cell Carcinoma | COMPLETED | NCT01062178 |
| Definity | Other | Phase PHASE2 | Renal Cell Carcinoma | COMPLETED | NCT01062178 |
| Placebo N-acetylcysteine | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Placebo losartan | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Losartan | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| N-acetylcysteine | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Placebo N-acetylcysteine | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Placebo losartan | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Losartan | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| N-acetylcysteine | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Placebo N-acetylcysteine | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Placebo losartan | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Losartan | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| N-acetylcysteine | Other | Phase PHASE1 | Aging | COMPLETED | NCT01384591 |
| Definity | Other | Phase PHASE2 | Cardiac Catheterization | COMPLETED | NCT03243942 |
| Definity | Other | Phase PHASE2 | Cardiac Catheterization | COMPLETED | NCT03243942 |
| Sestamibi | Other | Phase PHASE3 | Kawasaki Disease | COMPLETED | NCT00162032 |
| Sestamibi | Other | Phase PHASE3 | Kawasaki Disease | COMPLETED | NCT00162032 |
| Gadofosveset Triodium | Other | Preclinical | Pulmonary Embolism | COMPLETED | NCT01165892 |
| Gadofosveset Triodium | Other | Preclinical | Pulmonary Embolism | COMPLETED | NCT01165892 |
| Gadofosveset Triodium | Other | Preclinical | Pulmonary Embolism | COMPLETED | NCT01165892 |
| Definity | Other | Phase PHASE4 | Myocardial Perfusion Imaging | COMPLETED | NCT03173716 |
| [3H] BMS747158 | Other | Phase PHASE1 | Coronary Artery Disease | COMPLETED | NCT00930631 |
| [3H] BMS747158 | Other | Phase PHASE1 | Coronary Artery Disease | COMPLETED | NCT00930631 |
| BMS747158 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00707538 |
| BMS747158 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00707538 |
| BMS747158 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00707538 |
| BMS747158 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00707499 |
| BMS747158 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00707499 |
| LMI 1195-101 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT00891241 |
| LMI 1195-101 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT00891241 |
| LMI 1195-101 | Other | Phase PHASE1 | Heart Failure | COMPLETED | NCT00891241 |
| 99mTechnicium (sestamibi or tetrofosmin) | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01347710 |
| Flurpiridaz F18 | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01347710 |
| 99mTechnicium (sestamibi or tetrofosmin) | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01347710 |
| Flurpiridaz F18 | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01347710 |
| 99mTechnicium (sestamibi or tetrofosmin) | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01347710 |
| Flurpiridaz F18 | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01347710 |
| DEFINITY® | Other | Phase PHASE4 | Cardiovascular Disease | COMPLETED | NCT00625365 |
| DEFINITY | Other | Phase PHASE3 | Cardiac Disease | COMPLETED | NCT03571672 |
| DEFINITY® | Other | Phase PHASE3 | Cardiac Disease | COMPLETED | NCT03719612 |
| DEFINITY® | Other | Phase PHASE3 | Cardiac Disease | COMPLETED | NCT03719612 |
| DEFINITY® | Other | Phase PHASE3 | Cardiac Disease | COMPLETED | NCT03719612 |
| Perflutren Lipid Microsphere Injectable Suspension | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00162370 |
| Perflutren Lipid Microsphere Injectable Suspension | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00162370 |
| Perflutren Lipid microsphere | Other | Phase PHASE2 | Chronic Kidney Diseases | COMPLETED | NCT03196076 |
| Ultrasound | Other | Preclinical | Atheroma | COMPLETED | NCT03466255 |
| Ultrasound | Other | Preclinical | Atheroma | COMPLETED | NCT03466255 |
| PYLARIFY | Other | Preclinical | Prostate Cancer | NOT_YET_RECRUITING | NCT05712473 |
| PYLARIFY | Other | Preclinical | Prostate Cancer | NOT_YET_RECRUITING | NCT05712473 |
| 18F- DCFPyl Injection | Other | Phase PHASE2 | Prostate Cancer Diagnosis | NOT_YET_RECRUITING | NCT05820724 |
| No PSMA PET | Other | Phase PHASE2 | Prostate Cancer Diagnosis | NOT_YET_RECRUITING | NCT05820724 |
| PSMA PET scan | Other | Phase PHASE2 | Prostate Cancer Diagnosis | NOT_YET_RECRUITING | NCT05820724 |
| bicycle stress echocardiography | Other | Preclinical | Mitral Annulus Calcification | COMPLETED | NCT04093973 |
| bicycle stress echocardiography | Other | Preclinical | Mitral Annulus Calcification | COMPLETED | NCT04093973 |
| Definity | Other | Phase PHASE2 | Chronic Exertional Compartment Syndrome | COMPLETED | NCT05247541 |
| Definity | Other | Phase PHASE2 | Chronic Exertional Compartment Syndrome | COMPLETED | NCT05247541 |
| Definity | Other | Preclinical | Endoleaks | COMPLETED | NCT01005212 |
| Definity | Other | Preclinical | Endoleaks | COMPLETED | NCT01005212 |
| Sulfur hexafluoride lipid microspheres | Other | Phase PHASE2 | Von-Hippel Lindau | COMPLETED | NCT03907657 |
| Perflutren lipid microsphere | Other | Phase PHASE2 | Von-Hippel Lindau | COMPLETED | NCT03907657 |
| Carotid Contrast Enhanced Ultrasound | Other | Preclinical | Atherosclerosis | RECRUITING | NCT05416385 |
| Carotid Contrast Enhanced Ultrasound | Other | Preclinical | Atherosclerosis | RECRUITING | NCT05416385 |
| Logiq E9 Scanner (Contrast-enhanced ultrasound) | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT02764801 |
| Ultrasound contrast agent (Contrast-enhanced ultrasound) | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT02764801 |
| Logiq E9 Scanner (Contrast-enhanced ultrasound) | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT02764801 |
| Ultrasound contrast agent (Contrast-enhanced ultrasound) | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT02764801 |
| Control Arm | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04557501 |
| PSMA PET/CT guided intensification of therapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04557501 |
| Control Arm | Other | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04557501 |
| PSMA PET/CT guided intensification of therapy | Drug | Phase PHASE3 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04557501 |
| 3D HI and SHI of UCA | Other | Phase PHASE4 | Breast Cancer | COMPLETED | NCT01490892 |
| 3D HI and SHI of UCA | Other | Phase PHASE4 | Breast Cancer | COMPLETED | NCT01490892 |
| Contrast-Enhanced Subharmonic Ultrasound Imaging | Other | Phase EARLY_PHASE1 | Adnexal Mass | COMPLETED | NCT03297112 |
| Perflutren Lipid Microspheres | Other | Phase EARLY_PHASE1 | Adnexal Mass | COMPLETED | NCT03297112 |
| 64Cu-LNTH-1363S | Other | Phase PHASE1 | Metastatic Sarcoma | RECRUITING | NCT06298916 |
| 64Cu-LNTH-1363S | Other | Phase PHASE1 | Metastatic Sarcoma | RECRUITING | NCT06298916 |
| Piflufolastat F 18 Intravenous Solution [PYLARIFY] | Other | Phase PHASE4 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06074510 |
| Piflufolastat F 18 Intravenous Solution [PYLARIFY] | Other | Phase PHASE4 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06074510 |
| Piflufolastat F 18 Intravenous Solution [PYLARIFY] | Other | Phase PHASE4 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT06074510 |
| Piflufolastat F18 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT05394259 |
| piflufolastat F 18 | Other | Phase PHASE2 | Clear Cell Renal Cell Carcinoma | WITHDRAWN | NCT07084909 |
| piflufolastat F 18 | Other | Phase PHASE2 | Clear Cell Renal Cell Carcinoma | WITHDRAWN | NCT07084909 |
| Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Other | Phase PHASE1 | Relapsed / Refractory Osteosarcoma | RECRUITING | NCT07357519 |
| LNTH2403 Phase 1 dose | Other | Phase PHASE1 | Relapsed / Refractory Osteosarcoma | RECRUITING | NCT07357519 |
| Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Other | Phase PHASE1 | Relapsed / Refractory Osteosarcoma | RECRUITING | NCT07357519 |
| LNTH2403 Phase 1 dose | Other | Phase PHASE1 | Relapsed / Refractory Osteosarcoma | RECRUITING | NCT07357519 |
| PET scan quantifying sympathetic denervation using [18F]-LMI1195 | Other | Preclinical | Sudden Cardiac Arrest | ACTIVE_NOT_RECRUITING | NCT03493516 |
| PET scan quantifying sympathetic denervation using [18F]-LMI1195 | Other | Preclinical | Sudden Cardiac Arrest | ACTIVE_NOT_RECRUITING | NCT03493516 |
| PET scan quantifying sympathetic denervation using [18F]-LMI1195 | Other | Preclinical | Sudden Cardiac Arrest | ACTIVE_NOT_RECRUITING | NCT03493516 |
| Total-body PET imaging | Other | Preclinical | Prostate Cancer | ENROLLING_BY_INVITATION | NCT05160480 |
| Total-body PET imaging | Other | Preclinical | Prostate Cancer | ENROLLING_BY_INVITATION | NCT05160480 |
| Total-body PET imaging | Other | Preclinical | Prostate Cancer | ENROLLING_BY_INVITATION | NCT05160480 |
| Ultrasound-Induced Microbubble Cavitation | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Definity | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Ultrasound-Induced Microbubble Cavitation | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Definity | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Ultrasound-Induced Microbubble Cavitation | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Definity | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Cancer | RECRUITING | NCT07501650 |
| Piflufolastat F18 | Other | Phase PHASE1 | Pancreatic Cancer | RECRUITING | NCT05394259 |
Total products: 130